Related by context. All words. (Click for frequent words.) 81 multicentre 81 prospective randomized 80 randomized multicenter 80 randomized controlled 80 multicenter randomized 79 randomized placebo controlled 78 randomized clinical 78 placebo controlled 75 multicenter study 75 multicenter prospective 75 randomized double 74 Phase III randomized 74 multicenter randomized double 74 randomized 74 multicentre randomized 73 blind randomized placebo 73 blind randomized 73 multicenter clinical 73 prospective multicenter 73 prospective observational 72 prospective randomized controlled 72 double blind placebo 71 randomized controlled trial 71 randomized Phase III 71 label multicenter 71 multicentre randomized double 70 placebo controlled randomized 70 randomized controlled clinical 70 placebo controlled clinical 70 nonrandomized 69 placebo controlled Phase 69 multicenter randomized controlled 68 multicenter Phase II 68 multicenter randomized placebo controlled 68 double blinded randomized 68 dose escalation study 68 blind placebo controlled 68 controlled multicenter 67 Multicenter 67 clinical trial 67 multicentre study 67 TMC# C# 67 prospective randomized placebo 66 blind multicenter 66 Phase IIIb 66 placebo controlled Phase III 66 randomized clinical trials 66 label dose escalation 66 Phase 2b study 66 multicenter phase 66 prospective randomized multicenter 65 blind randomized controlled 65 Phase 1b clinical 65 RE LY 65 phase IIIb 65 double blinded placebo 65 randomized trials 65 randomized multicentre 65 Phase 2b trial 65 substudy 65 placebo controlled studies 65 TAXUS ATLAS 64 Edge STudy 64 randomized multicenter trial 64 prospective nonrandomized 64 blinded placebo controlled 64 multicenter placebo controlled 64 EVEREST II 64 dose escalation trial 64 prospective cohort 64 masked placebo controlled 64 randomized Phase 64 RE LY ® 64 NO# [002] 64 phase IIb clinical 64 multicenter randomized clinical 64 prospective multicenter randomized 64 PRECiSE 64 observational study 64 randomized blinded 64 Phase IIIb study 64 Phase IIb trial 64 multicenter multinational 63 Phase 2a clinical 63 phase IIa clinical 63 dose escalation Phase 63 multicenter Phase III 63 subanalysis 63 dose dose escalation 63 multicenter Phase 63 Phase 2a trial 63 randomized controlled trials 63 Phase Ib clinical 63 prospective multicentre 63 Phase 2b 63 HCV SPRINT 63 TG MV 63 phase IIa 63 CALGB 63 label multicenter Phase 63 randomized Phase IIb 63 Randomized 62 Sorafenib HCC Assessment 62 ONTARGET 62 phase IIb 62 ECASS 62 phase Ib 62 Phase Ib 62 label dose titration 62 Phase III clinical 62 AIR CF3 62 label multicenter randomized 62 Phase IIa 62 randomized crossover 62 REALITY Trial 62 Carotid Revascularization Endarterectomy vs. 62 Phase IIb clinical 62 Phase IIb 62 LUX Lung 62 active comparator 62 multicentre prospective 62 Phase III placebo controlled 62 ascending dose 62 Phase #/#a 62 confirmatory Phase III 62 randomized controlled clinical trials 61 landmark ATHENA 61 dose escalation clinical 61 retrospective cohort study 61 blinded randomized 61 BRIM2 61 ENDEAVOR IV 61 placebo controlled trials 61 OLYMPIA registry 61 Phase 2b clinical 61 Multicentre 61 EchoCRT 61 NCCTG 61 multicenter trials 61 NICE SUGAR 61 Phase 1b trial 61 Phase 1b 61 Clinical Antipsychotic Trials 61 ExTRACT TIMI 60 EORTC 60 Endovascular Valve Edge 60 randomized controlled Phase 60 Phase IIa trial 60 Prostate Lung Colorectal 60 AIR2 Trial 60 meta analysis 60 blinded randomized controlled 60 Phase III VISTA 60 ADVANCE PD 60 ABSORB trial 60 Phase III 60 phase III ACCLAIM 60 Randomised 60 Phase IIa clinical 60 Prospective Randomized 60 SPIRIT IV 60 BRIM3 60 viral kinetic 59 NSABP 59 longitudinal cohort study 59 Randomized Study 59 blinded randomized placebo controlled 59 SPIRIT III 59 RTOG 59 Phase III multicenter 59 AIR CF2 59 dose escalation 59 Val HeFT 59 CLL8 59 Phase III pivotal 59 CARE HF 59 randomized blinded placebo 59 Randomized controlled 59 randomized controlled multicenter 59 trials RCTs 59 TAXUS IV 59 Phase 2a 59 SWOG 59 Phase IIIb clinical 59 BCIRG 59 pharmacokinetic PK 59 Phase Ib II 59 HPTN 59 controlled multicenter Phase 59 unblinding 59 retrospective cohort 59 blind placebo 59 Placebo controlled 58 Pivotal Trial 58 Multi Ethnic Study 58 multicentre randomized controlled 58 ASCEND HF 58 pivotal Phase 58 TAXUS V 58 BR.# 58 PFO migraine 58 recurrent malignant glioma 58 Ovarian PLCO Cancer 58 Radiation Therapy Oncology 58 retrospective observational study 58 subgroup analyzes 58 prospectively randomized 58 Thrombolysis 58 PREVAIL 58 Stenting Trial CREST 58 phase 2a 58 tolerability 58 Randomized Evaluation 58 treatment naive genotype 58 ENESTnd 58 VADT 58 IMPROVE HF 58 pivotal Phase III 58 pivotal bioequivalence 58 Phase 2b kidney transplant 58 MEND CABG 58 NCT# ClinicalTrials.gov 58 dabigatran etexilate 58 DAPT 58 MADIT II 58 Phase 2b randomized 58 randomized Phase 2b 58 prospectively defined 58 CUSTOM II 58 DAPT Study 58 HORIZONS AMI trial 58 pharmacokinetics PK 58 e HEALING 58 observational studies 58 AIR CF1 57 CAMMS# 57 ASTEROID 57 confirmatory clinical 57 NSABP B 57 ROCKET AF 57 SPIRIT FIRST 57 VICTOR E1 57 ENDEAVOR II 57 placebo controlled dose escalation 57 Atherosclerosis MESA 57 APEX PD 57 AIM HIGH 57 randomized #:# 57 Observational Study 57 Myocardial Infarction Study 57 observational cohort study 57 phase IIb study 57 riociguat 57 Intervention Effectiveness 57 single ascending dose 57 EURIDIS 57 Phase III randomized controlled 57 treatment naïve genotype 57 Group RTOG 57 symptomatic BPH 57 bronchial thermoplasty 57 prospective observational cohort 57 controlled dose escalation 57 liver transplant recipients 57 prospective multicenter study 57 metastatic HRPC 57 Cholesterol Levels SPARCL 57 Phase Ia 57 BARI 2D 57 Phase 1a 57 phase Ib clinical 57 multicenter randomized Phase 57 ACTEMRA 57 non inferiority 57 Aggressive Reduction 57 HCV RESPOND 2 57 placebo controlled clinical trials 57 Screening Trial 57 oral deforolimus 57 BETAS 56 Phase 1a clinical 56 CLARITY study 56 STRIDE PD 56 RIO Lipids 56 Cardiac Allograft Rejection 56 TRITON TIMI 56 clinical trials 56 registrational Phase 56 ToGA 56 acute PAO 56 ENDEAVOR 56 everolimus eluting stent 56 phase IIb trial 56 longitudinal study 56 PRoFESS 56 multicentric 56 STENT 56 Intervention Trial 56 number NCT# ClinicalTrials.gov 56 Phase IIB 56 CURRENT OASIS 7 56 Prostate Cancer Prevention 56 GEM OS1 56 sunitinib malate 56 GISSI HF 56 noninferiority 56 COMFORT II 56 relapsing multiple sclerosis 56 STICH trial 56 MADIT CRT 56 PFO closure 56 HeFT 56 PICSO ® 56 HYVET 56 phase III SIMPADICO 56 ongoing Phase 1b 56 Multicenter Study 56 randomized placebo 56 AVERROES 56 Myocardial Infarction 56 Acute Ischemic Stroke 56 rALLy clinical trial 56 Heart Failure Trial 56 LEXIVA r 56 relapsed APL 56 patients undergoing CABG 56 Intervention Trial GAIT 56 Sequenced Treatment Alternatives 56 carotid artery stenting 56 evaluating REVLIMID 56 multiple ascending dose 55 EINSTEIN DVT 55 acute ischemic stroke 55 ABSORB clinical 55 prospective longitudinal 55 unblinded 55 clinical pharmacology studies 55 International Verapamil SR 55 Phase III psoriasis 55 CYPHER R Sirolimus eluting 55 ascending doses 55 multinational multicenter randomized 55 LCP AtorFen 55 Phase Ib IIa clinical 55 Acute Decompensated Heart Failure 55 SYNTAX 55 RRMS patients 55 registrational trial 55 BOLDER II 55 rosuvastatin 55 TAXUS VI 55 Acute Myocardial Infarction 55 nab paclitaxel 55 Randomized Phase 55 ACRIN 55 MERLIN TIMI 55 Glucosamine Chondroitin Arthritis 55 MIST II 55 RG# ITMN 55 Phase IIb III 55 ABCSG 55 pharmacokinetic PK study 55 patients undergoing percutaneous 55 dosing regimens 55 PRE SURGE 55 ascending dose study 55 Raloxifene Evaluation MORE 55 ATTRACT 55 TAXUS TM 55 sunitinib 55 safety tolerability pharmacokinetic 55 comparing XIENCE V 55 ADAGIO study 55 pharmacodynamics 55 Communities ARIC study 55 HCV infected 55 RezularTM 55 IMPROVE IT 55 Randomized Double Blind Placebo 55 placebo controlled multicenter 55 blind randomized multicenter 55 PRESEPT 55 Left Ventricular Dysfunction 55 ZYBRESTAT fosbretabulin 55 blind multicentre 55 RESOLUTE 55 RE LY trial 55 Study ADCS 55 neoadjuvant 55 recurrent GBM 55 APTIVUS 55 meta analyzes 55 Chronic Heart Failure 55 RSD# oral 55 Randomized Clinical Trial 55 II Clinical Trial 55 oral rivaroxaban 55 transcatheter aortic valve implantation 55 Multiethnic Study 55 CYPHER R stent 54 VITAL Trial 54 CIMZIA TM certolizumab pegol 54 NEVO RES 54 CYPHER Stent 54 APPRAISE 54 HORIZONS AMI 54 Trandolapril 54 IIa clinical 54 dose titration 54 Feasibility Trial 54 Initiated Phase 54 TIMI Study Group 54 AVADO 54 PROPEL 54 GOUT 54 pharmacokinetic studies 54 Amrubicin 54 CHAMPION PCI 54 ataluren 54 pharmacodynamics PD 54 randomized multicenter Phase III 54 Phase Ib clinical trials 54 ACCOMPLISH 54 Phase III clinical trials 54 Digital Mammographic Imaging 54 carotid stenting 54 PERSEUS 54 Evaluation WISE 54 chemoradiotherapy 54 Phase III Clinical Trial 54 TRANSFORMS 54 sirolimus eluting stents 54 ACTEMRA TM 54 Ovarian Cancer Screening 54 null responder HCV 54 pharmacodynamic profile 54 Gynecologic Oncology Group 54 Clinical Study 54 dyskinesia PD LID 54 Prospective Multicenter 54 RoACTEMRA 54 thorough QT 54 Denufosol 54 safety tolerability pharmacokinetics 54 non valvular atrial 54 carotid endarterectomy CEA 54 CUSTOM III 54 SYNTAX trial 54 anti arrhythmic drug 54 Group B CALGB 54 ALLHAT 54 ENDEAVOR clinical 54 PRECISE 54 CALGB # [002] 54 teriflunomide 54 NCT# 54 TEMSO 54 Angiox R 54 rFVIIa 54 Controlled Trial 54 Phase III trials 54 CATIE AD 54 PRIMO CABG 54 Alzheimer Disease Neuroimaging Initiative 54 Clinical Trial 54 denufosol 54 Zilver PTX 54 MIVI III 54 posaconazole 54 afatinib 54 PreCISe 54 #mg/day [001] 54 HOPE TOO 54 dose escalation phase 54 PARTNER Trial 54 CLARITY TIMI 54 epidemiologic studies 54 PREVENT IV 54 multicenter clinical trials 53 TAXUS 53 observational cohort 53 analgesic efficacy 53 Betaferon ® 53 Phase Ib study 53 SORT OUT III 53 ACUITY trial 53 fosbretabulin 53 Phase #b/#a 53 mg administered orally 53 NATRECOR ® 53 pharmacokinetic 53 Intervention Effectiveness CATIE 53 Phase III confirmatory 53 ENGAGE AF TIMI 53 SUCCEED trial 53 eptifibatide 53 PLCO 53 relapsing remitting MS RRMS 53 XIENCE V Stent System 53 dose cohorts 53 darunavir ritonavir 53 GAMMAGARD 53 Clinical Outcomes Utilizing Revascularization 53 evaluating tivozanib 53 RECORD1 53 ACTIVE W 53 ARCOXIA 53 Bowel Project NSABP 53 Phase III randomized placebo 53 paclitaxel eluting stents 53 Microplasmin 53 SIMPADICO 53 safety tolerability 53 RE MODEL 53 Relieve Depression 53 DU #b 53 brivaracetam 53 paclitaxel eluting stent 53 Prospective Randomized Trial 53 pegylated interferon alfa 2b 53 COPAXONE R 53 Placebo Controlled 53 COU AA 53 Co Principal Investigator 53 Adalimumab 53 icatibant 53 CYPHER ® Sirolimus eluting 53 refractory CLL 53 adalimumab 53 satraplatin Phase 53 CYPHER R Stent 53 pharmacodynamic effects 53 observer blinded randomized 53 colesevelam HCl 53 postmenopausal women 53 NOXAFIL Oral Suspension 53 Dacogen injection 53 fostamatinib 53 EDEMA3 53 factorial design 53 ATTAIN 53 Cohort 53 Phase 1b clinical trials 53 retrospectively analyzed 53 Infarct 53 dose regimens 53 LITHE 53 GetGoal Phase III 53 XIENCE V Everolimus Eluting 53 Randomized Controlled 53 TMC# r 53 Spine Patient Outcomes 53 cohort 53 XIENCE V demonstrated 53 everolimus eluting stents 53 post hoc 53 RESOLUTE clinical 53 designated HVTN 53 SCD HeFT 53 evaluable patients 53 cetrorelix 53 MADIT CRT trial 53 ORACLE MS 53 registrational 53 Platelet Inhibition 53 unstable angina UA 53 randomized #:#:# 53 IMPACT DCM 53 Trial ASCOT 53 relapsing remitting multiple sclerosis 53 PreCISe study 53 Stenting Trial 53 Long Lesion 53 EOquin TM 53 REMEDIAL II 53 Val MARC 53 PROPEL trial 53 severe aortic stenosis 53 Framingham Offspring Study 53 Augment Injectable 53 ALTTO 53 Women Ischemia Syndrome 53 ELCAP 53 radical cystectomy 53 Prostate AdenoCarcinoma Treatment 53 Patency 53 Rosuvastatin 53 Meta analyzes 53 DSMB 53 dosage regimens 53 Endeavor Resolute DES 53 Phase 1b dose escalation 53 sequential dose escalation 53 Phase Ib IIa 53 Controlled Study 52 mg QD 52 CYPHER ® Stent 52 recurrent glioblastoma multiforme 52 Asthma Intervention 52 ritonavir boosted 52 BOLDER 52 tolerability profile 52 Zenvia Phase III 52 UPLIFT 52 HeFH 52 paclitaxel poliglumex 52 acute coronary syndromes ACS 52 relapsed MM 52 CombAT 52 juvenile idiopathic arthritis 52 Ranolazine 52 Health Initiative WHI 52 TAXUS stent 52 ARDIS 52 pain palliation 52 vicriviroc 52 Phase III metastatic melanoma 52 NSTE ACS 52 ischemic cardiomyopathy 52 Diabetic Macular Edema 52 IIa trial 52 RADIANT 52 hemodialysis patients 52 Efficacy 52 Blind Placebo Controlled 52 phase IIb III 52 landmark ATHENA trial 52 PCI ExTRACT TIMI 52 Randomized Double blind 52 Randomized Placebo Controlled 52 PRIMO CABG2 52 Multicenter Automatic Defibrillator Implantation 52 Phase 2b clinical trials 52 stage IIIB 52 adult chronic ITP 52 antiretroviral naïve 52 bendamustine 52 axitinib 52 dosing cohorts 52 Cooperative Oncology 52 TAXUS Liberte 52 Alpha Tocopherol Beta Carotene 52 Pivotal Study 52 iPrEx 52 EQUIP OB 52 OPT CHF 52 Study Evaluating 52 CIMZIA TM 52 NEVO 52 Polyp Prevention Trial 52 AIDS Clinical Trials 52 administered subcutaneously 52 BoNTA 52 CATIE 52 Randomized Phase II 52 pharmacokinetics 52 MOTIVATE 52 CA4P 52 LUMINATE 52 visilizumab 52 bosentan 52 ZoMaxx 52 eluting stent 52 ATACAND 52 NEVO ™ 52 Phase III Trial 52 Neoadjuvant 52 prespecified 52 ID NCT# 52 ATIR TM 52 Rheos System 52 sirolimus eluting stent 52 interferon beta 1b 52 eprotirome 52 MSI #F 52 transplantation HSCT 52 CAPRISA 52 longitudinal studies 52 COSIRA trial 52 pancreatic neuroendocrine tumors 52 retinal vein occlusion 52 Endarterectomy 52 recurrent glioma 52 LibiGel Phase III 52 PROMUS Element Stent 52 ILLUMINATE 52 EXPLORE Xa 52 SCH # 52 ConclusionThis 52 Genous stent 52 Oral Fingolimod 52 ANCHOR trial 52 mg BID 52 retrospectively reviewed 52 FAME Study 52 nulliparous women 52 Phase II 52 EVA 3S 52 TIMI 52 National Surgical Adjuvant 52 CAPRIE 52 NP2 Enkephalin 52 pertuzumab 52 undergone radical prostatectomy 52 CORD II 52 Multiple Ascending Dose 52 sorafenib Nexavar 52 mycophenolate mofetil 52 LHRH receptor positive 52 Myocet 52 Phase IIb kidney transplant 52 AVAiL 52 Eluting Coronary Stent System 52 Phase III Pivotal 52 Tocilizumab 52 eculizumab 52 Dialysis Outcomes 51 varespladib 51 AEGR 51 Wisconsin Sleep Cohort 51 primary endpoint 51 crizotinib PF # 51 Cardiovascular Risk 51 ORMD 51 SYMMETRY trial 51 acute coronary syndrome 51 IBS C 51 League Against Rheumatism 51 Drug Eluting Stent System 51 MADIT 51 ACCLAIM 51 NATRECOR R 51 ICON7 51 Phase IIb trials 51 dose placebo controlled 51 KRN# 51 radiographic outcomes 51 SPARCL 51 chronic myocardial ischemia 51 superficial bladder cancer 51 galiximab 51 ticagrelor 51 RG# [001] 51 fluvastatin 51 Atherosclerosis Risk 51 metreleptin 51 hepatocellular carcinoma HCC 51 Coronary Artery Bypass Graft 51 APEX AMI trial 51 CHARISMA trial 51 retinal vein occlusion induced 51 carotid stents 51 NEO3 51 fully bioabsorbable 51 Group ECOG 51 Edwards SAPIEN valve 51 atherothrombotic disease 51 Stenting 51 PROMACTA 51 HuMax EGFr 51 elacytarabine 51 Multicenter Randomized Double 51 Swedish Mammography Cohort 51 RCTs 51 antiretroviral naive 51 glatiramer acetate 51 sirolimus eluting 51 MEND CABG II 51 daily Infergen 51 PROTECT AF 51 UKPDS 51 prucalopride 51 Ophena TM 51 canakinumab 51 Alzheimer Disease Cooperative 51 NLX P# 51 lacosamide 51 sulodexide 51 Aggressive Drug Evaluation 51 Traficet EN 51 chronic ITP patients 51 REGARDS 51 PRADAXA 51 ZACTIMA 51 PD LID 51 ExCell study 51 #mg QD [002] 51 coronary intervention 51 CardioFit 51 Neovascular AMD 51 candesartan cilexetil 51 ADMIRE HF 51 Osteoporotic Fractures 51 MGd 51 darunavir r 51 Vascugel ® 51 weekly subcutaneous injections 51 ZYBRESTAT 51 onset AF 51 ONTARGET R 51 PREZISTA r 51 Angiographic 51 REVLIMID lenalidomide 51 PRTX 51 ClinicalTrials.gov 51 Enzastaurin 51 INTERCEPT platelets 51 IMPACT DCM clinical 51 INTERHEART study 51 CINQUIL 51 hypertensive patients 51 REYATAZ r 51 Clinical Efficacy 51 RE SURGE 51 evaluating Actimmune 51 rt PA 51 opioid induced bowel dysfunction 51 lubiprostone 51 polyarticular 51 ELACYT 51 Zenvia ™ 51 COPERNICUS 51 Trial Evaluating 51 multicenter randomized Phase III 51 cinacalcet 51 CRESTOR #mg 51 pomalidomide 51 biliary tract cancer 51 Degarelix 51 neratinib 51 fallopian tube cancers 51 REVIVE Diabetes 51 atypical Hemolytic Uremic Syndrome 51 ganetespib 51 Initiate Phase 51 lorcaserin Phase 51 HIV HCV coinfected 51 By JENNIFER LEARN 51 duplex ultrasonography 51 forodesine 51 Pre RELAX AHF 51 Ozarelix 51 Cimzia ® certolizumab pegol 51 Taxus Stent 51 statin therapy 51 AZILECT ® 51 carotid artery stenting CAS 51 Hepatocellular Carcinoma HCC 51 ISAR REACT 51 Phase #b/#a clinical 51 Phase IIA 51 de novo kidney transplant 51 dirucotide MBP# 51 dexpramipexole 51 MIVI TRUST 51 TAXUS Liberte Stent 51 multicentre phase 51 ACCORD 51 ACCORD Eye 51 cluster randomized controlled 51 Acute Coronary Syndromes ACS 51 histologically confirmed 51 TOLAMBA 51 elotuzumab 51 ALLEGRO 51 relapsed myeloma 51 NCIC CTG 51 Allovectin 7 ® 51 Safinamide 51 MYTHOS trial 51 ADHF 51 ENDEAVOR III 51 longitudinal observational study 51 Primary endpoints 51 Non Alcoholic Steatohepatitis 51 unfractionated heparin UFH 51 ARIXTRA 51 Multicenter Randomized 51 viral kinetics 51 Relieve Depression STAR 51 IMPACT IMmunotherapy 51 stage IIIb IV 51 antiepileptic drug 51 Phase IIa trials 51 underwent liver transplantation 51 Elocalcitol 51 Communities ARIC Study 51 Lipid Lowering Treatment 51 Group NCCTG 51 irbesartan 51 NSABP C 51 Nutrition EPIC 51 pitavastatin 51 oral ridaforolimus 51 IIa clinical trial 51 secondary efficacy endpoints 51 Tyrima 51 thromboembolic events 51 IFN alfa 50 Prospective Investigation 50 DCCT 50 Scandinavian Simvastatin Survival 50 monotherapy 50 Dr. Kandzari 50 VIRAMUNE XR 50 GEM OS2 50 ancrod 50 prospectively 50 desvenlafaxine succinate 50 tolvaptan 50 NCCTG N# 50 TEC #OL 50 Unstable Angina 50 everolimus 50 CONQUER OB 50 heFH 50 ACCEDE 50 preclinical efficacy 50 macrovascular disease 50 Phase III Clinical Trials 50 Ophena 50 biologic therapy 50 noninfectious uveitis 50 landmark ATHENA study 50 CIMZIA ™ 50 RAPAFLO R 50 tanespimycin 50 Dapagliflozin 50 EmbraceAC 50 JAK inhibitor 50 investigational oral 50 MabThera rituximab 50 pharmacodynamic 50 edoxaban 50 Remission Maintenance 50 pharmacodynamic PD 50 Pivotal Clinical Trial 50 TAXUS Liberte Long 50 liver resection 50 #mg BID [001] 50 FOLOTYN ® 50 mixed hyperlipidemia 50 assessing T DM1 50 tocilizumab 50 epoetin alpha 50 intravenous dosing 50 Medidur TM FA 50 GISSI 50 Acute Coronary Syndromes 50 Double Blind Placebo 50 Current Controlled Trials 50 TASQ 50 NeuroFlo 50 HF ACTION 50 CaPSURE 50 Teriflunomide 50 Phenoptin 50 Pharmacokinetics PK 50 Pivotal Phase 50 VESTASYNC 50 PROactive Study 50 ALSYMPCA 50 Parkinson disease levodopa induced 50 acute decompensated heart 50 trastuzumab emtansine T DM1 50 mg/m2 dose 50 ERSPC 50 STEALTH C 50 castrate resistant prostate cancer 50 recurrent ovarian cancer 50 platelet inhibitor 50 NeuroStar TMS Therapy 50 Randomized Double Blind 50 evaluating carfilzomib 50 Subgroup analysis 50 TORISEL 50 budesonide foam 50 secondary endpoint 50 APTIVUS r 50 n = 50 investigational drug 50 SABCS 50 Radiology Imaging Network ACRIN 50 thrombus aspiration 50 nesiritide 50 inhibitor RG# 50 transfemoral 50 AERAS-#/Crucell Ad# 50 Phase IIb IIIa 50 #:# randomization 50 Autologous Stem Cell Transplantation 50 oral diclofenac 50 PROMUS R 50 severe oral mucositis 50 CANCIDAS 50 metaanalysis 50 peginterferon alfa 2b 50 metastatic renal cell carcinoma 50 Patient Registry